On February 9, Health Action InternationaI (HAI) published a report entitled 'Access to insulin: current challenges and constraints' and The Lancet Diabetes & Endocrinology published a companion review 'Constraints and challenges in access to insulin: a global perspective
The underlining message in the report and review is that insulin remains out of reach for approximately half of those who need it.
While, as David Beran (lead author) is the first to admit, 'Insulin access is a complex challenge', there are clear issues that affect access to insulin. These include the global insulin market being dominated by three multinational manufacturers, import duties affecting the price of insulin entering different countries, and mark- ups, taxes and other costs in the pharmaceutical supply chain impacting patient prices in the public and private sectors.
Link leads to: http://haiweb.org/wp-content/uploads/2016/02/ACCISS_report_2015-final.pdf
Link leads to: http://www.thelancet.com/journals/landia/article/PIIS2213-8587(15)00521-5/abstract
Link leads to: http://haiweb.org/publication/david-beran-speaks-lancet-diabetes-endocrinology-insulin-access/
Link leads to: http://haiweb.org/what-we-do/acciss/acciss-network/